Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamic Effect of Verucerfont and Emicerfont in IBS
NCT00511563Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Aug 2007
- Primary completion
- Nov 2012
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of verucerfont, emicerfont in irritable bowel syndrome (IBS), sponsored by GSK. Planned start Aug 2007; status: withdrawn.
02
Drugs
verucerfontemicerfont
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT00511563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00511563.